세계의 환각제 시장 - 규모, 점유율, 성장 분석 : 소스별, 유형별, 약제별, 용도별, 투여경로별, 최종사용자별, 유통채널별, 지역별 산업예측(2024-2031년)
Psychedelic Drugs Market Size, Share, Growth Analysis, By Source, By Type, By Drug, By Application, By Route of Administration, By End-User, By Distribution Channel, By Region - Industry Forecast 2024-2031
상품코드:1619055
리서치사:SkyQuest
발행일:2024년 12월
페이지 정보:영문 242 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계 환각제 시장 규모는 2022년 16억 달러로 평가되었고, 2023년 17억 9,000만 달러에서 2031년에는 44억 7,000만 달러로 성장하며, 예측기간(2024-2031년) CAGR은 12.1%로 성장할 전망입니다.
환각제 시장은 정신건강 치료의 중요성에 대한 의식 증가와 스트레스와 불안 등의 문제에 대처할 필요성에 의해 큰 성장이 예상되고 있습니다. 치료 옵션을 제공하고 여러 과제에도 불구하고 관심을 모으고 있습니다. 아메리카(미국의 정신위생 현상) 보고서와 같은 최근 데이터는 젊은이들 사이에서 심한 우울증의 발병이 증가하고 있음을 지적하고 있으며, 이러한 치료에 대한 수요가 더욱 높아지고 있습니다. 정부의 협력적인 노력과 국제 건강 프로그램은 시장 확대를 뒷받침할 것으로 예상됩니다. 분야로 자리매김합니다.
목차
소개
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차 데이터와 1차 데이터의 방법
시장 규모 예측
시장의 전제조건과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
억제요인과 과제
Porter's Five Forces 분석
주요 시장 인사이트
중요성공요인
경쟁도
주요 투자 기회
시장 생태계
시장의 매력 지수(2023년)
PESTEL 분석
거시경제지표
밸류체인 분석
가격 분석
규제 상황
특허 분석
사례 연구
고객과 구매 기준 분석
환각제 시장 규모 : 소스별 및 CAGR(2024-2031년)
시장 개요
합성
천연
환각제 시장 규모 : 유형별 및 CAGR(2024-2031년)
시장 개요
엠파토젠
해리제
기타
환각제 시장 규모 : 약제별 및 CAGR(2024-2031년)
시장 개요
감마하이드록시부티르산(GHB)
케타민
실로시빈
리젤구산디에틸아미드(LSD)
3,4-메틸렌디옥시메탄페타민(MDMA)
기타
환각제 시장 규모 : 용도별 및 CAGR(2024-2031년)
시장 개요
나루코렙시
치료 저항성 우울증
중증 우울증 장애
아편 중독
외상 후 스트레스 장애(PTSD)
기타
환각제 시장 규모 : 투여 경로별 및 CAGR(2024-2031년)
시장 개요
경구
흡입
주사 가능
환각제 시장 규모 : 최종 사용자별 및 CAGR(2024-2031년)
시장 개요
병원
전문 클리닉
홈케어
기타
환각제 시장 규모 : 유통 채널별 및 CAGR(2024-2031년)
시장 개요
병원 약국
소매 약국
온라인 약국
환각제 시장 규모 및 CAGR(2024-2031년)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카
기타 중동 및 아프리카
경쟁 정보
상위 5개사 비교
주요 기업의 시장 포지셔닝(2023년)
주요 시장 기업이 채용한 전략
시장의 최근 동향
기업의 시장 점유율 분석(2023년)
주요 기업의 기업 프로파일
기업 개요
제품 포트폴리오 분석
부문별 점유율 분석
수익의 전년대비 비교(2021-2023년)
주요 기업 프로파일
Pfizer Inc.(USA)
Johnson & Johnson(USA)
AbbVie Inc.(USA)
Jazz Pharmaceuticals(Ireland)
Compass Pathways(UK)
MindMed(Canada)
Atai Life Sciences(Germany)
Cybin Corp.(Canada)
Field Trip Health(Canada)
GH Research(Ireland)
Beckley Psytech(UK)
Seelos Therapeutics(USA)
Numinus Wellness Inc.(Canada)
Delix Therapeutics(USA)
Mydecine Innovations Group(Canada)
Revive Therapeutics Ltd.(Canada)
Entheon Biomedical(Canada)
Mind Cure Health Inc.(Canada)
PsyBio Therapeutics(USA)
Tryp Therapeutics(USA)
결론과 권장사항
JHS
영문 목차
영문목차
Global Psychedelic Drugs Market size was valued at USD 1.6 billion in 2022 and is poised to grow from USD 1.79 billion in 2023 to USD 4.47 billion by 2031, growing at a CAGR of 12.1% during the forecast period (2024-2031).
The psychedelic drug market is poised for significant growth, driven by heightened awareness of mental health treatment's importance and the need to address issues like stress and anxiety. The emergence of psychedelic drugs offers innovative treatment options for mental health disorders, attracting interest despite some challenges. Recent data, such as the 2022 State of Mental Health in America report, highlights a concerning rise in severe depressive episodes among youth, further fueling demand for these therapies. Collaborative government initiatives and mental health awareness programs are expected to bolster market expansion. While stringent regulations and potential side effects pose constraints, the sector's growing acceptance and research breakthroughs position it as a key area for investment and development in the coming years.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Psychedelic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Psychedelic Drugs Market Segmental Analysis
Global Psychedelic Drugs Market is segmented by source, type, drug, application, route of administration, end-user, distribution channel and region. Based on source, the market is segmented into synthetic and natural. Based on type, the market is segmented into empathogens, dissociatives and others. Based on drug, the market is segmented into gamma-hydroxybutyric acid (GHB), ketamine, psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA) and others. Based on application, the market is segmented into narcolepsy, treatment-resistant depression, major depressive disorder, opiate addiction, post-traumatic stress disorder (PTSD) and others. Based on route of administration, the market is segmented into oral, inhalation and injectable. Based on end-user, the market is segmented into hospitals, specialty clinics, homecare and others. Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Psychedelic Drugs Market
The global psychedelic drugs market is witnessing significant growth driven by the increasing acceptance of these substances for treating depression. Over the past decade, psychedelics have gained recognition for their therapeutic potential in mental health treatment, with researchers actively exploring their efficacy in alleviating symptoms of depression. Ongoing studies and advancements in psychedelic drug development have further enhanced their credibility and acceptance among healthcare professionals and patients alike. As promising results emerge from clinical trials, the popularity and demand for psychedelic therapies are surging, particularly in the United States and various other regions, positioning these factors as key market drivers.
Restraints in the Global Psychedelic Drugs Market
One significant constraint on the Global Psychedelic Drugs market is the elevated cost associated with these substances, which can hinder growth potential. The expensive nature of psychedelic drugs limits accessibility for many patients and consumers, potentially stifling widespread adoption and use. Moreover, the landscape is further complicated by stringent regulations and legal barriers, which can impede market expansion and innovation. These factors combined present challenges that the industry must navigate to achieve sustainable development and broader acceptance within the healthcare sector during the forecasted period. As a result, stakeholders must find solutions to alleviate these concerns for future market success.
Market Trends of the Global Psychedelic Drugs Market
The Global Psychedelic Drugs market is witnessing a notable trend towards the growth of hospital pharmacies, driven by heightened public consciousness surrounding mental health issues and the therapeutic potential of psychedelics. As these substances increasingly require prescriptions from medical professionals, hospital pharmacies are becoming essential distribution channels. This trend is further propelled by a growing body of research supporting the efficacy of psychedelics for specific indications, such as depression, anxiety, and PTSD. Consequently, stakeholders in the healthcare sector are prioritizing the integration of psychedelic therapies, thus fostering a dynamic environment for hospital pharmacies to expand their role in psychiatric treatment.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Patent Analysis
Case Studies
Customer & Buying Criteria Analysis
Global Psychedelic Drugs Market Size by Source & CAGR (2024-2031)
Market Overview
Synthetic
Natural
Global Psychedelic Drugs Market Size by Type & CAGR (2024-2031)
Market Overview
Empathogens
Dissociatives
Others
Global Psychedelic Drugs Market Size by Drug & CAGR (2024-2031)
Market Overview
Gamma-Hydroxybutyric Acid (GHB)
Ketamine
Psilocybin
Lysergic Acid Diethylamide (LSD)
3,4-Methylenedioxymethamphetamine (MDMA)
Others
Global Psychedelic Drugs Market Size by Application & CAGR (2024-2031)
Market Overview
Narcolepsy
Treatment-Resistant Depression
Major Depressive Disorder
Opiate Addiction
Post-Traumatic Stress Disorder (PTSD)
Others
Global Psychedelic Drugs Market Size by Route Of Administration & CAGR (2024-2031)
Market Overview
Oral
Inhalation
Injectable
Global Psychedelic Drugs Market Size by End-User & CAGR (2024-2031)
Market Overview
Hospitals
Specialty Clinics
Homecare
Others
Global Psychedelic Drugs Market Size by Distribution Channel & CAGR (2024-2031)
Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Psychedelic Drugs Market Size & CAGR (2024-2031)
North America (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
USA
Canada
Europe (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
